Mystic Pharmaceuticals new VRx2 delivery platform technology that could enable needle-free vaccines has been granted US patent.
The VRx2 delivery platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.
One of the primary applications for this technology will be to develop needle-free vaccines for pandemic and bioterror threats that are safer, easier and less costly to produce and deploy, stated Dr. C.J. Peters, director for Biodefense in the Center for Biodefense and Emerging Infectious Diseases at the University of Texas Medical Branch.
A wide range of drugs, proteins, peptides and biologics require an uninterrupted cold chain of refrigeration or freezing during storage, transport and deployment to maintain stability and potency.
Cold chain management adds cost and complicates the task of deploying drugs or vaccines to large populations. Freeze drying reduces or eliminates the need for cold chain management by converting the drug or vaccine from a liquid form to a stable powder using processes such as spray drying or lyophilization.
Freeze dried vaccines must be reconstituted prior to use, a process that requires trained medical personnel and is difficult to do under adverse field conditions often encountered in a crisis situation.
Mystic’s patented unit dose blister technology enables freeze dried drugs or biologics to be pre-packaged in novel intranasal or ophthalmic delivery systems and automatically reconstituted and self-administered by the consumer with the push of a button.
Mystic’s technology will simplify and accelerate the packaging, deployment and delivery of drugs and biologics to protect the public safety in a crisis situation, Mystic officials said.
VRx2 blisters are multi-chambered storing the freeze dried drug or biologic in one chamber and the diluent in a separate chamber. The blister is pre-loaded into the delivery system.
Reconstitution occurs within the blister during the dispensing process and can be made virtually transparent to the end user or caregiver administering the drug.
This approach reduces many of the risks typically found with needle based reconstitution delivery such as contamination, inaccurate mixing procedures and loss of sterility.
VRx2 delivery systems will be available for intranasal, ophthalmic and oral (sub-lingual) applications.
The issued patent covers Mystic’s proprietary unit dose blister technology for packaging of drugs or biologics that have been freeze dried to powder form to improve stability, reduce the need for cold chain management and enable auto-reconstitution to a liquid form at the time of administration, the company stated in a press release.
Mystic Pharmaceuticals is an integrated specialty pharmaceutical company based in Austin, Texas. Mystic provides precision unit dose delivery systems for pharmaceuticals, biopharmaceuticals and biologics for ophthalmic and intranasal applications.